<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03523104</url>
  </required_header>
  <id_info>
    <org_study_id>CPD-LRRK2R</org_study_id>
    <nct_id>NCT03523104</nct_id>
  </id_info>
  <brief_title>Chinese PD-LRRK2 Registry</brief_title>
  <official_title>The Chinese Parkinson's Disease With LRRK2 Variants Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xiangya Hospital of Central South University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the Chinese PD-LRRK2 Registry(CPD-LRRK2R) is to develop a database of patients
      of Parkinson's disease with leucine-rich repeat kinase 2 (LRRK2) gene variants in mainland
      China.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Parkinson's disease (PD) is the second most common disorder among neurodegenerative diseases.
      LRRK2 missense mutations are the most common known genetic cause of PD. However, some
      polymorphisms of LRRK2 such as G2385R and R1628P can also affect the risk of developing PD.
      The investigators aim to establish a database of PD with LRRK2 variants and characterize the
      clinical manifestation of these patients in mainland China.

      Method:

        1. Peripheral blood from patients has been tested to have LRRK2 gene variants.

        2. Clinical manifestation will be measured by scales and neurological tests. Standard
           scales include: Unified Parkinson's Disease Rating Scale(UPDRS), Hoehn-Yahr stages,
           Non-Motor Symptoms Scale (NMSS), mini-mental state examination (MMSE), Parkinson disease
           sleep scales (PDSS), Rapid Eye Movement Sleep Behaviour Disorder Questionnaire(RBDQ-HK),
           Epworth Sleepiness Scale (ESS), Rome III functional constipation scale, the Scale for
           Outcomes in PD for Autonomic Symptoms (SCOPA-AUT), Parkinson Fatigue Scale (PFS),
           Cambridge-Hopkins Restless Legs Syndrome questionnaire (CHRLSq), Hyposmia rating
           scale(HRS), Hamilton depression scale, the 39-item Parkinson's Disease
           Questionnaire(PDQ-39), Freezing of gait scale(FOG), dyskinesia related scales,
           Wearing-off scale(WO).

        3. The investigators will also exam the blood biomarkers of PD such as uric acid and
           peripheral inflammatory markers.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2017</start_date>
  <completion_date type="Anticipated">February 1, 2027</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2027</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Database of Parkinson's disease with LRRK2 variants</measure>
    <time_frame>10 years</time_frame>
    <description>Establish the database of Parkinson's disease with LRRK2 variants in mainland China.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical feature</measure>
    <time_frame>10 years</time_frame>
    <description>Characterize the clinical feature in patients of Parkinson's disease with LRRK2 variants</description>
  </primary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Parkinson Disease</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      extraction of DNA from peripheral blood
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        PD patients with LRRK2 variants
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with PD by the United Kingdom Parkinson's Disease Society Brain
             Bank clinical diagnostic criteria or other standard criteria; PD patients detected
             with positive LRRK2 variants

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jifeng Guo, Ph.D.</last_name>
    <phone>+8613974936815</phone>
    <email>guojifeng2003@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Beisha Tang, Ph.D.</last_name>
    <phone>+8613974856709</phone>
    <email>bstang7398@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jifeng Guo, Ph.D.</last_name>
      <phone>+8613974936815</phone>
      <email>guojifeng2003@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Qiying Sun, Ph.D.</last_name>
      <phone>+8615874907260</phone>
      <email>sunqiying2015@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Guo JF, Li K, Yu RL, Sun QY, Wang L, Yao LY, Hu YC, Lv ZY, Luo LZ, Shen L, Jiang H, Yan XX, Pan Q, Xia K, Tang BS. Polygenic determinants of Parkinson's disease in a Chinese population. Neurobiol Aging. 2015 Apr;36(4):1765.e1-1765.e6. doi: 10.1016/j.neurobiolaging.2014.12.030. Epub 2015 Jan 6.</citation>
    <PMID>25623333</PMID>
  </results_reference>
  <results_reference>
    <citation>Li K, Tang BS, Liu ZH, Kang JF, Zhang Y, Shen L, Li N, Yan XX, Xia K, Guo JF. LRRK2 A419V variant is a risk factor for Parkinson's disease in Asian population. Neurobiol Aging. 2015 Oct;36(10):2908.e11-5. doi: 10.1016/j.neurobiolaging.2015.07.012. Epub 2015 Jul 11.</citation>
    <PMID>26234753</PMID>
  </results_reference>
  <results_reference>
    <citation>Yao LY, Guo JF, Wang L, Yu RH, Sun QY, Pan Q, Xia K, Tang BS, Shen L. LRRK2 Pro755Leu variant in ethnic Chinese population with Parkinson's disease. Neurosci Lett. 2011 May 9;495(1):35-8. doi: 10.1016/j.neulet.2011.03.030. Epub 2011 Mar 22.</citation>
    <PMID>21406209</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang L, Guo JF, Nie LL, Xu Q, Zuo X, Sun QY, Yan XX, Tang BS. A novel LRRK2 mutation in a mainland Chinese patient with familial Parkinson's disease. Neurosci Lett. 2010 Jan 14;468(3):198-201. doi: 10.1016/j.neulet.2009.10.080. Epub 2009 Oct 29.</citation>
    <PMID>19879329</PMID>
  </results_reference>
  <results_reference>
    <citation>Zhang Y, Sun Q, Yi M, Zhou X, Guo J, Xu Q, Tang B, Yan X. Genetic Analysis of LRRK2 R1628P in Parkinson's Disease in Asian Populations. Parkinsons Dis. 2017;2017:8093124. doi: 10.1155/2017/8093124. Epub 2017 Oct 25. Review.</citation>
    <PMID>29209554</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2018</study_first_submitted>
  <study_first_submitted_qc>May 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2018</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

